Browse

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “…

The poet didn’t say “sing to me, Muse, of a man with optimized endocrine panels," writes urologist Elizabeth Dray.